BioSpace News Archive

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois based-Eton Pharmaceuticals, Inc. (NASDAQ: ETON).

Forecast to 2030,’ thoroughly examines the Brain Reading Robots industry to provide essential data & information for the targeted readers.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA®.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria.

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, provides an update to the announcement released earlier regarding the Company’s request for an immediate suspension of trading in the Company’s ordinary shares on AIM which took effect from 12.30 p.m.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services (“HHS”) and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento’s Chairman and CEO Henry Ji. Governor Thompson’s appointment is effective immediately.

Hepion Pharmaceuticals, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Friday, July 22, 2022 at 9:00 a.m. Eastern Time with respect to Proposal 4, as described in Hepion’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 19, 2022.

Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022.

Veru Inc., a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, announced the granting of inducement awards to three new employees.